BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23935154)

  • 41. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
    Gömöri E; Pál J; Kovács B; Dóczi T
    Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy with Gamma Knife radiosurgery and antisense EGFR for malignant glioma in vitro and orthotopic xenografts.
    Li Y; Jia Q; Zhang J; Han L; Xu D; Zhang A; Zhang Y; Zhang Z; Pu P; Kang C
    Oncol Rep; 2010 Jun; 23(6):1585-91. PubMed ID: 20428813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status.
    Kaloshi G; Mokhtari K; Carpentier C; Taillibert S; Lejeune J; Marie Y; Delattre JY; Godbout R; Sanson M
    J Neurooncol; 2007 Sep; 84(3):245-8. PubMed ID: 17415524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts.
    Broniscer A; Hwang SN; Chamdine O; Lin T; Pounds S; Onar-Thomas A; Chi L; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
    Brain Pathol; 2018 Jan; 28(1):112-120. PubMed ID: 28032389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-584-3p, a novel tumor suppressor and prognostic marker, reduces the migration and invasion of human glioma cells by targeting hypoxia-induced ROCK1.
    Xue H; Guo X; Han X; Yan S; Zhang J; Xu S; Li T; Guo X; Zhang P; Gao X; Liu Q; Li G
    Oncotarget; 2016 Jan; 7(4):4785-805. PubMed ID: 26715733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma.
    Verma BK; Kondaiah P
    J Neurooncol; 2020 Sep; 149(2):209-217. PubMed ID: 32803659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
    Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
    Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers.
    Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C
    Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.
    Shiras A; Bhosale A; Shepal V; Shukla R; Baburao VS; Prabhakara K; Shastry P
    Neoplasia; 2003; 5(6):520-32. PubMed ID: 14965445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
    Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
    BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression analysis of the autosomal recessive primary microcephaly genes MCPH1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas.
    Hagemann C; Anacker J; Gerngras S; Kühnel S; Said HM; Patel R; Kämmerer U; Vordermark D; Roosen K; Vince GH
    Oncol Rep; 2008 Aug; 20(2):301-8. PubMed ID: 18636190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ProBDNF and its receptors are upregulated in glioma and inhibit the growth of glioma cells in vitro.
    Xiong J; Zhou L; Yang M; Lim Y; Zhu YH; Fu DL; Li ZW; Zhong JH; Xiao ZC; Zhou XF
    Neuro Oncol; 2013 Aug; 15(8):990-1007. PubMed ID: 23576602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas.
    Han MZ; Huang B; Chen AJ; Zhang X; Xu R; Wang J; Li XG
    Oncol Rep; 2017 Feb; 37(2):903-912. PubMed ID: 28075478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification.
    Dekanić A; Dintinjan RD; Budisavljević I; Pećanić S; Butorac MŽ; Jonjić N
    Diagn Pathol; 2011 Nov; 6():108. PubMed ID: 22050898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CNTF receptor subunit α as a marker for glioma tumor-initiating cells and tumor grade: laboratory investigation.
    Lu J; Ksendzovsky A; Yang C; Mehta GU; Yong RL; Weil RJ; Park DM; Mushlin HM; Fang X; Balgley BM; Lee DH; Lee CS; Lonser RR; Zhuang Z
    J Neurosurg; 2012 Dec; 117(6):1022-1031. PubMed ID: 23061382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.